TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Status:
RECRUITING
Trial end date:
2038-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER2-low or HER2-0) metastatic breast cancer.
The names of the study drugs involved in this study are:
* Datopotamab deruxtecan (a type of antibody drug conjugate)
* Trastuzumab deruxtecan (a type of antibody drug conjugate)
Phase:
PHASE2
Details
Lead Sponsor:
Ana C Garrido-Castro, MD
Collaborators:
AstraZeneca Translational Breast Cancer Research Consortium